{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:08:01Z","timestamp":1778544481333,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370309"],"award-info":[{"award-number":["81370309"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700263"],"award-info":[{"award-number":["81700263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.biopha.2019.108773","type":"journal-article","created":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T19:56:10Z","timestamp":1552766170000},"page":"108773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting"],"prefix":"10.1016","volume":"113","author":[{"given":"Zong-Ming","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-Qing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Rong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru-Qiong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2019.108773_bib0005","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.108773_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejvs.2007.01.004","article-title":"New antiplatelet strategies in atherothrombosis and their indications","volume":"34","author":"Fontana","year":"2007","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.biopha.2019.108773_bib0015","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2019.108773_bib0020","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0032-1301417","article-title":"High platelet reactivity and antiplatelet therapy resistance","volume":"38","author":"Linden","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.biopha.2019.108773_bib0030","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"Frelinger","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.108773_bib0040","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2005.07.056","article-title":"Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0045","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0050","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2019.108773_bib0055","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.108773_bib0060","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0065","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","article-title":"Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study","volume":"115","author":"Angiolillo","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2019.108773_bib0070","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/eurheartj\/ehl489","article-title":"A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days","volume":"28","author":"von Beckerath","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2019.108773_bib0075","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacc.2014.03.051","article-title":"Variability of individual platelet reactivity over time in patients treated with clopidogrel insights from the ELEVATE-TIMI 56 trial","volume":"64","author":"Hochholzer","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0085","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc08-2064","article-title":"Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions","volume":"32","author":"Angiolillo","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2019.108773_bib0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1681\/ASN.2010020220","article-title":"Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention","volume":"22","author":"Htun","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2019.108773_bib0095","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/j.ajkd.2011.12.027","article-title":"Association of estimated GFR with platelet inhibition in patients treated with clopidogrel","volume":"59","author":"Muller","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.biopha.2019.108773_bib0100","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0105","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","article-title":"High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI","volume":"306","author":"Parodi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2019.108773_bib0110","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2019.108773_bib0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point of care assay: a 12-month follow-up","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2019.108773_bib0120","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157488407779422302","article-title":"The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance","volume":"2","author":"Rosemary","year":"2007","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108773_bib0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","article-title":"Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations","volume":"84","author":"Myrand","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.108773_bib0135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","article-title":"Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17","volume":"69","author":"Li-Wan-Po","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108773_bib0140","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/ndt\/gft027","article-title":"Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options","volume":"28","author":"Morel","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biopha.2019.108773_bib0145","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2019.108773_bib0150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(92)90445-O","article-title":"Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel","volume":"44","author":"Savi","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108773_bib0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.108773_bib0160","first-page":"29","article-title":"Pharmacokinetic profile of 14C-labeled clopidogrel","volume":"25","author":"Lins","year":"1999","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.biopha.2019.108773_bib0165","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.biopha.2019.108773_bib0170","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.ijcard.2012.05.100","article-title":"Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis","volume":"167","author":"Aradi","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0175","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ahj.2011.09.003","volume":"162","author":"Woo","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2019.108773_bib0180","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","article-title":"A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure","volume":"104","author":"Park","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2019.108773_bib0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.108773_bib0190","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2019.108773_bib0195","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1253\/circj.CJ-09-0019","article-title":"Impact of CYP2C19 polymorphism on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan","volume":"73","author":"Jinnai","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.biopha.2019.108773_bib0200","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1253\/circj.CJ-12-1095","article-title":"Relationship between CYP2C19 loss-of-function polymorphism and platelet Reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation","volume":"77","author":"Nakata","year":"2013","journal-title":"Circ. J."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218388206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218388206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:10:27Z","timestamp":1778541027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218388206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":40,"alternative-id":["S0753332218388206"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108773","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"108773"}}